Trial | NCT01660620  Report issue

Official Title

Topical Betaxolol for the Prevention of Retinopathy of Prematurity

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    betaxolol ...

  • Study Participants

    23
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.
Study Started
Apr 30
2011
Primary Completion
Nov 30
2011
Study Completion
Nov 30
2011
Last Update
Jan 03
2013
Estimate

Drug Betaxolol

Drug topical betaxolol

given topically

betaxolol Experimental

betaxolol 0.25% 2 per day for 3 weeks

placebo Placebo Comparator

masked labeling also 2 per day administration

Criteria 

Inclusion Criteria:

<1251 grms birth weight

Exclusion Criteria:

ocular defect
No Results Posted